Long non-coding RNAs in osteosarcoma

被引：92

作者：

Chen, Ruiling ^{[1
]}

Wang, Gangyang ^{[1
]}

Zheng, Ying ^{[1
]}

Hua, Yingqi ^{[1
]}

Cai, Zhengdong ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Shanghai Bone Tumor Inst, Sch Med,Dept Orthopaed, Shanghai, Peoples R China

来源：

ONCOTARGET | 2017年 / 8卷 / 12期

关键词：

osteosarcoma; lncRNA; pathogenesis; biomarkers; therapeutic targets; PROMOTES CELL-PROLIFERATION; CANCER STEM-CELLS; POOR-PROGNOSIS; METASTATIC OSTEOSARCOMA; EXPRESSION PROFILE; TUMOR-SUPPRESSOR; DRUG-RESISTANCE; MALAT1; PROMOTES; UP-REGULATION; LUNG-CANCER;

D O I：

10.18632/oncotarget.14726

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Long non-coding RNAs (lncRNAs) with more than 200 nuleotides, have been explored to participate in various cancer types including osteosarcoma (OS), which is the most common kind of primary bone tumors with high morbidity in infants and adolescents. These oncogenic or tumor suppressive lncRNAs regulate OS pathogenesis, such as cell growth, proliferation, invasion, migration, metastasis and cell apoptosis, serve as independent prognostic biomarkers or play a significant role in multidrug resistance (MDR) in OS cells. In this review, we attempt to dissect the participation of lncRNAs in pathogenesis of OS and their potential clinical values, and also provide an outlook for viable biomarkers and therapeutic targets in OS.

引用

页码：20462 / 20475

页数：14

共 112 条

[1] Cancer stem cells in solid tumors [J].